Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 13/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | HTR7 | P34969 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4025816 | 0.79 | TACR1 (0.42) | TACR1POLBKMT2A | |
| SCHEMBL4026763 | 0.79 | TACR1 (0.42) | TACR1POLBKMT2A | |
| SCHEMBL6064294 | 0.76 | TACR1 (0.54) | TACR1RIPK1 | |
| SCHEMBL6064290 | 0.76 | TACR1 (0.54) | TACR1RIPK1 | |
| SCHEMBL6550098 | 0.75 | TACR1 (0.53) | TACR1RIPK1 | |
| SCHEMBL2486149 | 0.74 | TACR1 (0.41) | TACR1MTNR1B | |
| SCHEMBL2484439 | 0.74 | TACR1 (0.41) | TACR1MTNR1B | |
| SCHEMBL2484442 | 0.74 | TACR1 (0.41) | TACR1MTNR1B | |
| SCHEMBL5411632 | 0.73 | TACR1 (0.58) | TACR1 | |
| SCHEMBL5748393 | 0.73 | TACR1 (0.43) | TACR1OPRL1KMT2ARIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7276509-B2 | Piperidine derivatives and their use as antagonists of tachykinins | GLAXO GROUP LIMITED (GB) | 2007-10-02 | — | — | US | disclosed |
| US-20050096313-A1 | Piperidine derivatives and their use as antagonists of tachykinins | GLAXO GROUP LIMITED (GB) | 2005-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050096313-A1 | Piperidine derivatives and their use as antagonists of tachykinins | NPSR1, TACR1, OPRL1 | TACR1 2/4885MTNR1B 331/4885OPRL1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.